Multiple Sclerosis Implementation Network (Registry)

NCT07415824 | Recruiting

• 1 other identifier: HSC-SPH-24-0515 (Registry)
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 3

Brief Summary

The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life. This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (2)

• Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale

  Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.

  5 years

• Perception of cognitive impairment as assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) Scale

  Total score on the MSNQ ranges from 0 to 60, with a higher score indicating greater perceived cognitive impairment.

  5 years

Study Arms (1)

Patients with Multiple Sclerosis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Clinics in the United States treating MS patients.

You may qualify if:

• diagnosed with Multiple Sclerosis
• can speak and understand English comfortably

Sponsors & Collaborators

• The University of Texas Health Science Center, Houston: lead
• Novartis: collaborator
• Multiple Sclerosis Association of America: collaborator
• The University of Texas at Austin: collaborator

Study Sites (3)

Multiple Sclerosis Association of America

Cherry Hill, New Jersey, 08034, United States

RECRUITING

The University of Texas at Austin

Austin, Texas, 78712, United States

RECRUITING

The University of Texas Health Science Center at Houston (UTHealth Houston)

Houston, Texas, 77030, United States

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Amanda Montague, EdM

  Multiple Sclerosis Association of America

  STUDY DIRECTOR

Central Study Contacts

Amanda Montague, EdM

CONTACT

800-532-7667; AMontague@MYMSAA.org

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 29, 2026
• First Posted: February 17, 2026
• Study Start: April 28, 2025
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: February 17, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)